Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Atossa Genetics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,779
  • Shares Outstanding, K 5,647
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,120 K
  • 60-Month Beta 3.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.65
  • Number of Estimates 1
  • High Estimate -0.65
  • Low Estimate -0.65
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.36 +170.59%
on 03/05/19
7.39 -50.20%
on 03/14/19
+2.16 (+142.11%)
since 02/22/19
3-Month
0.80 +360.00%
on 12/26/18
7.39 -50.20%
on 03/14/19
+2.74 (+291.49%)
since 12/21/18
52-Week
0.80 +360.00%
on 12/26/18
7.39 -50.20%
on 03/14/19
-2.98 (-44.74%)
since 03/22/18

Most Recent Stories

More News
Estimated Revenues Continue to Rise for U.S. and Global Medical Device Markets

The U.S. medical device industry has seen its revenues continue to increase and it is poised is to become the global leader of this expanding market. It seems as though each new projection breaks through...

DERM : 12.99 (-4.63%)
ATOS : 3.68 (-1.34%)
BPTH : 21.98 (+18.94%)
AVGR : 0.88 (-4.36%)
SOLY : 7.82 (-1.67%)
Atossa Genetics Announces Receipt of $10 Million

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that...

ATOS : 3.68 (-1.34%)
Thinking about buying stock in Atossa Genetics Inc., Canopy Growth Corp., Facebook Inc., Micron Technology Inc., or Oxbridge Holdings?

InvestorsObserver issues critical PriceWatch Alerts for ATOS, CGC, FB, MU, and OXBR.

MU : 41.62 (-5.39%)
ATOS : 3.68 (-1.34%)
FB : 164.34 (-1.05%)
Atossa Genetics Announces FDA Approval of Oral Endoxifen for "Expanded Access" as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that...

ATOS : 3.68 (-1.34%)
Atossa Genetics Reports Results From "Expanded Access" Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues

, February 7, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other...

ATOS : 3.68 (-1.34%)
Atossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that...

ATOS : 3.68 (-1.34%)
Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019

Atossa Genetics Inc. (Nasdaq:ATOS) today issued the following letter from Dr. Steven C. Quay, President and CEO, to Atossa shareholders:

ATOS : 3.68 (-1.34%)
Thinking about buying stock in American Airlines, Aurora Cannabis Inc, Atossa Genetics, Chesapeake Energy or Tilray?

InvestorsObserver issues critical PriceWatch Alerts for AAL, ACB, ATOS, CHK, and TLRY.

CHK : 3.12 (-4.00%)
ATOS : 3.68 (-1.34%)
AAL : 30.57 (-2.80%)
Today's Research Reports on Trending Tickers: BioTelemetry and Atossa Genetics

NEW YORK, NY / ACCESSWIRE / January 10, 2019 / U.S. markets rose for the fourth consecutive session on Wednesday as minutes released from the Federal Reserve's meeting in December showed the Fed would...

ATOS : 3.68 (-1.34%)
BEAT : 64.07 (-6.41%)
4 Healthcare Stocks Looking To Set January Highs

CORAL GABLES, FL/ ACCESSWIRE / January 9, 2019 / The is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will...

ATOS : 3.68 (-1.34%)
ACST : 1.05 (-1.87%)
VSTM : 3.24 (-6.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ATOS with:

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

2nd Resistance Point 4.14
1st Resistance Point 3.91
Last Price 3.68
1st Support Level 3.51
2nd Support Level 3.35

See More

52-Week High 7.39
Fibonacci 61.8% 4.87
Fibonacci 50% 4.09
Last Price 3.68
Fibonacci 38.2% 3.32
52-Week Low 0.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar